

Docket No.: PF-0551 USN

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box PCT, Commissioner for Patents, Washington, D.C. 20231 on May 20, 2002.

By: [Signature]Printed: Lyza Finuliar

#5

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lal et al.

Title: NEUROTRANSMISSION ASSOCIATED PROTEINS

Serial No.: 09/720,530

Filing Date:

To Be Assigned

Examiner: To Be Assigned

Group Art Unit:

To Be Assigned

Box PCT

Commissioner for Patents

Washington, D.C. 20231

FEE TRANSMITTAL SHEET

Sir:

Transmitted herewith are the following for the above-identified application:

1. Return Receipt Postcard;
2. Response to Notification of Defective Response dated April 19, 2002 (2 pp.);
3. A Substitute Submission Under 37 CFR §1.821-1.825 Sequence Listing (1 pg.);
4. A Substitute Computer Readable Form (CRF) Diskette of the "Sequence Listing"; and
5. A Copy of the Notification of Defective Response (2 pp.).

The fee has been calculated as shown below.

☒ No additional Fee is required.☒ Please charge Deposit Account No. 09-0108 in the amount of : \$ 0

Applicants believe no fee is due with this communication. However, the Commissioner is hereby authorized to charge any additional fees required under 37 CFR 1.16 and 1.17, or credit overpayment to Deposit Account No. 09-0108. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

INCYTE GENOMICS, INC.

Date: 20 May 2002Cathleen M. Rocco

Cathleen M. Rocco

Reg. No. 46,172

Direct Dial Telephone: (650) 845-4587

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 845-4166

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box PCT, Commissioner for Patents, Washington, D.C. 20231 on May 20, 2002.

By: [Signature] Printed: Lyza Finuliar

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Lal et al.

Title: NEUROTRANSMISSION ASSOCIATED PROTEINS

Serial No.: 09/720,530

Filing Date:

To Be Assigned

Examiner: To Be Assigned

Group Art Unit:

To Be Assigned

Box PCT

Commissioner for Patents

Washington, D.C. 20231

**RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE
AND AMENDMENT DIRECTING ENTRY INTO THE SPECIFICATION**

Sir:

This paper is in response to the Notification of Defective Response mailed on April 19, 2002 for which a response is due on May 19, 2002 (copy attached).

Applicants submit this amendment to request entry of the enclosed paper copy of the sequence listing from International Application Number PCT/US99/15121 into the above-identified U.S. national phase patent application.

Applicants submit the documents listed below to complete the filing for the above-identified patent application.

1. A Substitute Submission Under 37 CFR §1.821 - 1.825 Sequence Listing (1 pg.); and
2. A Substitute Computer Readable Form (CRF) Diskette of the "Sequence Listing" of the above-identified USN application.

Docket No.: PF-0551 USN

Applicant's do not believe a fee is due with this filing. However, if the Patent Office deems that a fee is due, please charge Deposit Account No. **09-0108**.

If there are any questions regarding the above, the Examiner is invited to call the undersigned.

Respectfully submitted,
INCYTE GENOMICS, INC.

Date: 20 May 2002

Cathleen M. Rocco
Cathleen M. Rocco
Reg. No. 46,172
Direct Dial Telephone: (650) 845-4587

3160 Porter Drive
Palo Alto, California 94304
Phone: (650) 855-0555
Fax: (650) 849-8886

Incyte Pharmaceuticals, Inc.
Patent Department
Received

APR 29 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
United States Patent and Trademark Office
Washington, D.C. 20231
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/720,530	Preeti Lal	PF-0551 USN

INTERNATIONAL APPLICATION NO.

PCT/US99/15121

I.A. FILING DATE	PRIORITY DATE
07/02/1999	07/02/1998

Incyte Genomics Inc
3160 Porter Drive
Palo Alto, CA 94304

CONFIRMATION NO. 2356

371 FORMALITIES LETTER



OC000000007880434

Date Mailed: 04/19/2002

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

Applicant is required to complete the response within a time limit of **ONE MONTH** from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):
 - A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
 - A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
 - APPLICANT MUST PROVIDE:

- An initial or substitute computer readable form (CRF) of the "Sequence Listing."
- An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.

● For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

SHELBY J VIGIL

Telephone: (703) 305-3653

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/720,530	PCT/US99/15121	PF-0551 USN